COMP <GO>
HUMA vs AVXL // EV/EBITDA & P/E VALUATION
Humacyte Inc. (NASDAQ) VS. Anavex Life Sciences Corp. (NASDAQ) • 15-METRIC TALLY: HUMA 3
— AVXL 0
■ METRIC PARITY
LAST: $0.47 (-0.06%) • MKT CAP: $130.5M
valuation
—
LAST: $1.30 (0.00%) • MKT CAP: $120.5M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HUMA VS. AVXL)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HUMA | AVXL | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | -30.00% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 1/9 | +1.00 | HUMA | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 41.9 | 20.8 | +21.14 | HUMA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $130.5M | $120.5M | $10.0M | HUMA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HUMA REV | AVXL REV | HUMA GROSS % | AVXL GROSS % | HUMA FCF | AVXL FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.0M | $0 | -50.0% | — | -$105.9M | -$39.0M |
| FY 2024 | $0 | $0 | — | — | -$99.7M | -$30.8M |
| FY 2023 | $0 | $0 | — | — | -$73.3M | -$27.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HUMA // BETA —
AVXL // BETA —